SARAH ARSENEAULT: Open Payments
NPI 1235437468 · HIGGANUM, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,066 in 74 payments from 13 companies in 2025. Trend: 2023 $17 · 2024 $21 · 2025 $2,066
Food & beverage: $1,910Education: $156
| Company | Payments | Amount |
|---|---|---|
| QOL Medical, LLC | 9 | $401 |
| Janssen Biotech, Inc. | 12 | $393 |
| ABBVIE INC. | 18 | $368 |
| Madrigal Pharmaceuticals | 9 | $322 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $184 |
| Ardelyx, Inc. | 8 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $102 |
| EVOKE PHARMA, INC. | 2 | $32 |
| GENZYME CORPORATION | 1 | $29 |
| Amgen Inc. | 1 | $26 |
Products named: Sucraid, TREMFYA, REZDIFFRA, XIFAXAN, SKYRIZI, IBSRELA, RINVOQ, LINZESS.
Industry payments across CT — which companies pay providers there.
